Jeil 
Welcome,         Profile    Billing    Logout  
 11 Products   1 Disease  11 Products   14 Trials   398 News 
20 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Beova (vibegron) / Merck (MSD)
BEST, NCT05806164: Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence

Recruiting
4
432
US
Beta3-Agonists, Adrenergic [Mirabegron/Vibegron], OnabotulinumtoxinA 100 UNT [Botox], Botox
Women and Infants Hospital of Rhode Island, University of New Mexico, University of Alabama at Birmingham, University of California, San Diego, Howard University, Brown University, Patient-Centered Outcomes Research Institute
Urgency Urinary Incontinence
07/26
07/27
2018-003136-72: A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Men with Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

Not yet recruiting
3
300
Europe
Vibegron, URO-901, RVT-901, Film-coated tablet
Urovant Sciences GmbH, Urovant Sciences GmbH
Overactive Bladder (OAB) in men with Benign Prostatic Hyperplasia (BPH), Overactive bladder (OAB), Diseases [C] - Symptoms and general pathology [C23]
 
 
NCT03902080 / 2018-003135-30: Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

Completed
3
1105
Europe, Canada, US
Vibegron, RVT-901, MK-4618, KRP-114V, URO-901, Placebo
Urovant Sciences GmbH, Urovant Sciences GmbH
Overactive Bladder
06/23
06/23
2018-003135-30: Study to evaluate vibegron in men taking stable BPH medications who have overactive bladder symptoms

Not yet recruiting
3
1088
Europe
Vibegron, URO-901, RVT-901, Film-coated tablet
Urovant Sciences GmbH, Urovant Sciences GmbH
Overactive Bladder (OAB) in men with Benign Prostatic Hyperplasia (BPH), Overactive bladder (OAB), Diseases [C] - Symptoms and general pathology [C23]
 
 
NCT06987383: Vibegron - A Novel Treatment for Multisystem Functional Decline in Aging and Obesity

Not yet recruiting
3
40
US
Vibegron, Gemtesa, Placebo
Wake Forest University Health Sciences
Obesity
06/27
06/27
KANGUROO, NCT05491525 / 2021-000676-11: A Study of Vibegron in Pediatric Participants 2 Years to Less Than (<) 18 Years of Age With NDO and on CIC

Recruiting
2/3
85
US
Vibegron
Urovant Sciences GmbH, Urovant Sciences GmbH
Neurogenic Detrusor Overactivity
01/27
09/27
2100208, NCT06417177: Impact of Early Aging and Menopause on the Vascular Responses to Hypoxia

Recruiting
1
75
US
Placebo, Propranolol, Gemtesa
University of Missouri-Columbia
Aging, Menopause, Hypoxia, Vasodilation
07/25
07/25
NCT05067478: Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)

Completed
N/A
403
US
Vibegron, GEMTESA
Urovant Sciences GmbH
Overactive Bladder
07/24
07/24
NCT06438861: Role of Combination Therapy in Women With Refractory Overactive Bladder

Not yet recruiting
N/A
54
NA
Vibegron 75mg, Placebo
University of Alabama at Birmingham
Overactive Bladder Syndrome
08/26
12/26
nesuparib (JPI-547) / Jeil
PENELOPE, NCT06502743: First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer

Recruiting
2
92
RoW
Nesuparib, Pembrolizumab
Yonsei University, Onconic Therapeutics Inc., Merck Sharp & Dohme LLC
Endometrial Cancer, Recurrent Endometrial Carcinoma, Endometrial Carcinoma, Gynecologycal Cancer, Endometrial Neoplasms
12/27
12/27
NCT05475184: A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor

Active, not recruiting
2
58
RoW
JPI-547
Onconic Therapeutics Inc.
Ovarian Cancer
11/24
06/25
NCT05257993: Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer

Recruiting
1
30
RoW
JPI-547, modified FOLFIRINOX, Gemcitabine-nab-paclitaxel
Onconic Therapeutics Inc.
Pancreatic Ductal Adenocarcinoma
03/26
06/26
Jaqbo (zastaprazan) / Jeil
NCT05443984: JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis

Completed
3
300
RoW
JP-1366 20mg, Esomeprazole 40mg
Onconic Therapeutics Inc.
Erosive Esophagitis
01/23
01/23
NCT05448001: Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric Ulcer

Completed
3
329
RoW
JP-1366 20mg, Lansoprazole 30mg
Onconic Therapeutics Inc.
Gastric Ulcer
07/24
07/24
NCT06439563: Study to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic Ulcers

Recruiting
3
364
RoW
JP-1366 10 mg, Lanston Capsule 15 mg, JP-1366 10 mg placebo, Lanston Capsule 15 mg placebo
Onconic Therapeutics Inc.
Peptic Ulcer
08/27
12/27
NCT06850480: A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux Esophagitis

Recruiting
3
356
RoW
JP-1366 simulation tablets, Esomeprazole Magnesium (Nexium) simulation tablets
Livzon Pharmaceutical Group Inc.
Reflux Esophagitis (RE)
04/25
04/25
NCT05814809: Clinical Trial to Evaluate the Safety and Pharmacokinetics of JP-1366 in Healthy Adult Volunteers

Completed
1
30
RoW
JP-1366 20mg tablet, Zastaprazan 20mg, JP-1366 20mg capsule
Onconic Therapeutics Inc.
Healthy
10/22
11/22
NCT05712681: Clinical Trial to Evaluate Food-Effects on Pharmacokinetics and Pharmacodynamics of Oral Single Dose of JP-1366 Tablet in Healthy Volunteers

Completed
1
24
RoW
JP-1366 20mg tablet
Onconic Therapeutics Inc.
Healthy
05/23
05/23
NCT06952855: Observationa Study is a Prospective and Multi-institutional Observational Study.

Completed
N/A
5536
RoW
Jeil Pharmaceutical Co., Ltd.
Erosive Reflux Disease, Heartburn, Acid Regurgitation
04/25
04/25
dapagliflozin/olmesartan medoxomil (ATB-101) / Autotelic, Jeil
NCT05573477: Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes

Recruiting
3
248
RoW
ATB-1011, ATB-1012, ATB-1013, ATB-1011 placebo, ATB-1012 placebo, ATB-1013 placebo
Autotelicbio
Essential Hypertension, Diabetes Mellitus, Type 2
01/24
06/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Beova (vibegron) / Merck (MSD)
BEST, NCT05806164: Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence

Recruiting
4
432
US
Beta3-Agonists, Adrenergic [Mirabegron/Vibegron], OnabotulinumtoxinA 100 UNT [Botox], Botox
Women and Infants Hospital of Rhode Island, University of New Mexico, University of Alabama at Birmingham, University of California, San Diego, Howard University, Brown University, Patient-Centered Outcomes Research Institute
Urgency Urinary Incontinence
07/26
07/27
2018-003136-72: A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Men with Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

Not yet recruiting
3
300
Europe
Vibegron, URO-901, RVT-901, Film-coated tablet
Urovant Sciences GmbH, Urovant Sciences GmbH
Overactive Bladder (OAB) in men with Benign Prostatic Hyperplasia (BPH), Overactive bladder (OAB), Diseases [C] - Symptoms and general pathology [C23]
 
 
NCT03902080 / 2018-003135-30: Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

Completed
3
1105
Europe, Canada, US
Vibegron, RVT-901, MK-4618, KRP-114V, URO-901, Placebo
Urovant Sciences GmbH, Urovant Sciences GmbH
Overactive Bladder
06/23
06/23
2018-003135-30: Study to evaluate vibegron in men taking stable BPH medications who have overactive bladder symptoms

Not yet recruiting
3
1088
Europe
Vibegron, URO-901, RVT-901, Film-coated tablet
Urovant Sciences GmbH, Urovant Sciences GmbH
Overactive Bladder (OAB) in men with Benign Prostatic Hyperplasia (BPH), Overactive bladder (OAB), Diseases [C] - Symptoms and general pathology [C23]
 
 
NCT06987383: Vibegron - A Novel Treatment for Multisystem Functional Decline in Aging and Obesity

Not yet recruiting
3
40
US
Vibegron, Gemtesa, Placebo
Wake Forest University Health Sciences
Obesity
06/27
06/27
KANGUROO, NCT05491525 / 2021-000676-11: A Study of Vibegron in Pediatric Participants 2 Years to Less Than (<) 18 Years of Age With NDO and on CIC

Recruiting
2/3
85
US
Vibegron
Urovant Sciences GmbH, Urovant Sciences GmbH
Neurogenic Detrusor Overactivity
01/27
09/27
2100208, NCT06417177: Impact of Early Aging and Menopause on the Vascular Responses to Hypoxia

Recruiting
1
75
US
Placebo, Propranolol, Gemtesa
University of Missouri-Columbia
Aging, Menopause, Hypoxia, Vasodilation
07/25
07/25
NCT05067478: Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)

Completed
N/A
403
US
Vibegron, GEMTESA
Urovant Sciences GmbH
Overactive Bladder
07/24
07/24
NCT06438861: Role of Combination Therapy in Women With Refractory Overactive Bladder

Not yet recruiting
N/A
54
NA
Vibegron 75mg, Placebo
University of Alabama at Birmingham
Overactive Bladder Syndrome
08/26
12/26
nesuparib (JPI-547) / Jeil
PENELOPE, NCT06502743: First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer

Recruiting
2
92
RoW
Nesuparib, Pembrolizumab
Yonsei University, Onconic Therapeutics Inc., Merck Sharp & Dohme LLC
Endometrial Cancer, Recurrent Endometrial Carcinoma, Endometrial Carcinoma, Gynecologycal Cancer, Endometrial Neoplasms
12/27
12/27
NCT05475184: A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor

Active, not recruiting
2
58
RoW
JPI-547
Onconic Therapeutics Inc.
Ovarian Cancer
11/24
06/25
NCT05257993: Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer

Recruiting
1
30
RoW
JPI-547, modified FOLFIRINOX, Gemcitabine-nab-paclitaxel
Onconic Therapeutics Inc.
Pancreatic Ductal Adenocarcinoma
03/26
06/26
Jaqbo (zastaprazan) / Jeil
NCT05443984: JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis

Completed
3
300
RoW
JP-1366 20mg, Esomeprazole 40mg
Onconic Therapeutics Inc.
Erosive Esophagitis
01/23
01/23
NCT05448001: Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric Ulcer

Completed
3
329
RoW
JP-1366 20mg, Lansoprazole 30mg
Onconic Therapeutics Inc.
Gastric Ulcer
07/24
07/24
NCT06439563: Study to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic Ulcers

Recruiting
3
364
RoW
JP-1366 10 mg, Lanston Capsule 15 mg, JP-1366 10 mg placebo, Lanston Capsule 15 mg placebo
Onconic Therapeutics Inc.
Peptic Ulcer
08/27
12/27
NCT06850480: A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux Esophagitis

Recruiting
3
356
RoW
JP-1366 simulation tablets, Esomeprazole Magnesium (Nexium) simulation tablets
Livzon Pharmaceutical Group Inc.
Reflux Esophagitis (RE)
04/25
04/25
NCT05814809: Clinical Trial to Evaluate the Safety and Pharmacokinetics of JP-1366 in Healthy Adult Volunteers

Completed
1
30
RoW
JP-1366 20mg tablet, Zastaprazan 20mg, JP-1366 20mg capsule
Onconic Therapeutics Inc.
Healthy
10/22
11/22
NCT05712681: Clinical Trial to Evaluate Food-Effects on Pharmacokinetics and Pharmacodynamics of Oral Single Dose of JP-1366 Tablet in Healthy Volunteers

Completed
1
24
RoW
JP-1366 20mg tablet
Onconic Therapeutics Inc.
Healthy
05/23
05/23
NCT06952855: Observationa Study is a Prospective and Multi-institutional Observational Study.

Completed
N/A
5536
RoW
Jeil Pharmaceutical Co., Ltd.
Erosive Reflux Disease, Heartburn, Acid Regurgitation
04/25
04/25
dapagliflozin/olmesartan medoxomil (ATB-101) / Autotelic, Jeil
NCT05573477: Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes

Recruiting
3
248
RoW
ATB-1011, ATB-1012, ATB-1013, ATB-1011 placebo, ATB-1012 placebo, ATB-1013 placebo
Autotelicbio
Essential Hypertension, Diabetes Mellitus, Type 2
01/24
06/24

Download Options